• Home >
  • Health Library >
  • Compendium of Research >
  • Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Guan Z, Masood N, Srimuninnimit V, Chatterjee S, Gorospe C, Doval DC, Shim BY

https://www.ncbi.nlm.nih.gov/pubmed/27780749

Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7

PMID:27780749DOI:10.1016/j.clcc.2016.08.005